MIRA INFORM REPORT

 

 

Report No. :

317916

Report Date :

23.04.2015

 

IDENTIFICATION DETAILS

 

Name :

PHARMASCIENCE INC.

 

 

Registered Office :

6111 Avenue Royalmount, Ste 100, Montreal, Quebec H4P 2T4

 

 

Country :

Canada

 

 

Year of Establishment :

1983

 

 

Legal Form :

Federal Corporation – Profit

 

 

Line of Business :

Subject is engaged in develops and manufacturing and Selling generic pharmaceutical products

 

 

No. of Employee :

2,000

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

 

 

Payment Behaviour :

No complaints

 

 

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail : infodept@mirainform.com while quoting report number, name and date.

 

 

ECGC Country Risk Classification List – December 31, 2014

 

Country Name

Previous Rating

(30.09.2014)

Current Rating

(31.12.2014)

Canada

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

CANADA - ECONOMIC OVERVIEW

 

As a high-tech industrial society in the trillion-dollar class, Canada resembles the US in its market-oriented economic system, pattern of production, and high living standards. Since World War II, the impressive growth of the manufacturing, mining, and service sectors has transformed the nation from a largely rural economy into one primarily industrial and urban. The 1989 US-Canada Free Trade Agreement (FTA) and the 1994 North American Free Trade Agreement (NAFTA) (which includes Mexico) touched off a dramatic increase in trade and economic integration with the US, its principal trading partner. Canada enjoys a substantial trade surplus with the US, which absorbs about three-fourths of Canadian merchandise exports each year. Canada is the US's largest foreign supplier of energy, including oil, gas, uranium, and electric power. Given its abundant natural resources, highly skilled labor force, and modern capital plant, Canada enjoyed solid economic growth from 1993 through 2007. Buffeted by the global economic crisis, the economy dropped into a sharp recession in the final months of 2008, and Ottawa posted its first fiscal deficit in 2009 after 12 years of surplus. Canada's major banks, however, emerged from the financial crisis of 2008-09 among the strongest in the world, owing to the early intervention by the Bank of Canada and the financial sector's tradition of conservative lending practices and strong capitalization. Canada achieved marginal growth in 2010-14 and plans to balance the budget by 2015. In addition, the country's petroleum sector is rapidly expanding, because Alberta's oil sands significantly boosted Canada's proven oil reserves. Canada now ranks third in the world in proved oil reserves behind Saudi Arabia and Venezuela.

 

Source : CIA

 

Company name

 

PHARMASCIENCE INC.

 

 

Address

 

6111 Avenue Royalmount, Ste 100, Montreal, Quebec H4P 2T4

Canada

 

Telephone:                      +1 514-340-9800

 

Fax:                              +1 514-342-7764

 

Website:                       www.pharmascience.com

 

Corporate ID#:              4305817

 

State:                           Federal

 

Judicial form:                Federal Corporation – Profit

                                     A Federal Corporation is allowed to do business in all the 

                                    Country.

 

Date incorporated:        05-31-2005

 

Date founded:              1983

 

Stock:                           -

 

Value:                           -

 

 

Name of manager

 

David W. GOODMAN

 

 

ACTIVITIES & OPERATIONS

 

History:

 

Business issued from the merger of:

- PHARMASCIENCE INC.

- PENDOPHARM INC.

 

IST

 

Business:

 

Pharmascience, Inc. operates as a generic pharmaceutical company in Canada.

 

It develops and manufactures generic pharmaceutical products, including analgesic, antianginal, anti-infective, calcium/vitamins, cardiovascular, central nervous system, cholesterol reduction agents, dermatology, diabetes, endocrine therapy, GI therapy, ophthalmic, psychotherapeutics, and respiratory drug therapies; prescription medicines and consumer products (OTC/BTC) in various therapeutic categories, such as pain management, gastro-intestinal disorders, nasal hygiene, and oral re-hydration; and a range of dosage forms, including liquids, tablets, capsules, suppositories, powders, ophthalmics, sterile products for inhalation, gels, injectables, ointments, creams, nasal solutions, and suspensions.

The company also sells pharmaceutical products to hospitals and institutions in Canada; and supplies diagnostics and medical devices.

It provides healthcare products and related services to healthcare professionals and patients around the world.

The company was founded in 1983 and is based in Montréal, Canada. Pharmascience, Inc. operates as a subsidiary of Joddes Limited.

 

The Company is using several names including:

 

AEGERA THERAPEUTIQUES

AMD RITMED

LABORATOIRES ADAMS

LABORATOIRES LEE ADAMS

PENDOPHARM, A DIVISION OF PHARMASCIENCE INC.

PENDOPHARM, UNE DIVISION DE PHARMASCIENCE INC.

PHARMACAL DOMINION

PHARMACEUTIQUE ROYALMOUNT

PHARMACEUTIQUES RIVEX

RITMED

RIVEX, UNE DIVISION DE PHARMASCIENCE

ROYALMOUNT PHARMACEUTICALS

 

Staff:    2,000+

 

Operations & branches:

 

At the headquarters, we find the corporate office.

 

The Company maintains factories located:

 

5950, Côte-de-Liesse,

Mont-Royal, Quebec, H4T 1E2, Canada.

8580 De L'Esplanade

Montreal, Quebec, H2P 2S2, Canada.

6625 Abrams

Saint-Laurent, Quebec, H4S 1V9, Canada.

 

 

Shareholders

 

JODDES LIMITE

6111 Avenue Royalmount, Ste 100, Montreal, Quebec H4P 2T4

 

 

Management

 

David GOODMAN is Vice President and CEO.

Mr. Goodman served as an Executive Vice President of International Operations at Pharmascience Inc.

He holds a Bachelor's Degree in Commerce from McGill University, and his Ph.D. in Pharmacology from the University of Virginia

 

Morris GOODMAN is the Chairman and President

Mr. Morris Goodman co-founded Pharmascience Inc., in 1983 and serves as its Chairman of the Board.

Mr. Goodman graduated from the Faculty of Pharmacy at the University of Montreal in 1953 at the age of twenty-one, the youngest graduate of that faculty at the time, and obtained the University of Montreal’s Prize for Success.

 

Laurence MACGIRR serves as Chief Operations Officer of Pharmascience Inc.

Mr. Macgirr has a dynamic, personable leadership style. He is responsible for the strategic oversight of Pharmascience, inspiring out of the box thinking throughout Pharmascience Inc. During his 17 years at Ciba Vision Corp., he served as Vice President Sales-North American Lens Business and served as its General Manager-Canada.

Throughout his career, he has been a keen advocate of fostering strong relationships, connecting with clients and business partners alike, generating profound insights that benefit their business in unexpected ways.

He also participated in executive-focused programs at Harvard and Cornell.

He holds a Bachelor degree in Business Administration form York University.

 

As far as we know, they are involved in several corporations including:

 

JODDES LIMITE

6111 Avenue Royalmount, Ste 100, Montreal, Quebec H4P 2T4

 

PCRI INC.

6111 Avenue Royalmount, Ste 100, Montreal, Quebec H4P 2T4

 

 


FINANCIALS

 

In Canada, privately held corporations are not required to publish any financials.

 

On a direct call, a financial assistant controlled the present report but deferred any financials.

We sent a fax but no answer received.

 

However, sales estimate for year 2014 is in the range of CAD 750,000,000=

 

The business is said to be profitable.

 

 

Banks:  Banque de Montreal

                        Banque Nationale du Canada

                       

 

LEGAL FILINGS

 

Legal filings & complaints:

 

As of today date, there is no legal filing pending with the Courts.

 

Secured debts summary:   Several

 

 

COMPANY CREDIT HISTORY

 

Trade references:

 

Date reported:               March 2015

High credit:                   CAD 60,000

Now owing:                   0

Past due:                      0

Last purchase:              February 2015

Line of business:           Office supply

Paying status:               On terms

 

Date reported:               March 2015

High credit:                   CAD 3,500,000+

Now owing:                   0

Past due:                      0

Last purchase:              February 2015

Line of business:           Payroll

Paying status:               As agreed

 

Date reported:               March 2015

High credit:                   CAD 1,000

Now owing:                   0

Past due:                      0

Last purchase:              February 2015

Line of business:           Telecommunications

Paying status:               On terms

 

Domestic credit history:

 

National Credit Bureaus gave a satisfying credit rating.

 

According to our credit analysts, during the last 6 months, payments were prompt and regular.

 

Other comments:

 

The Company is developing a strong business.

The Company is in good standing.

This means that all local and federal taxes were paid on due date.

Last report was filed on 02-27-2015.

 

The risk is low.

 

Our opinion:

 

A business connection may be conducted.

 

 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.82

UK Pound

1

Rs.93.85

Euro

1

Rs.67.59

 

INFORMATION DETAILS

 

Analysis Done by :

DIV

 

 

Report Prepared by :

ASH

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.